177 related articles for article (PubMed ID: 20353772)
21. Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation.
Chen JF; Sonsalla PK; Pedata F; Melani A; Domenici MR; Popoli P; Geiger J; Lopes LV; de Mendonça A
Prog Neurobiol; 2007 Dec; 83(5):310-31. PubMed ID: 18023959
[TBL] [Abstract][Full Text] [Related]
22. Cannabinoid receptors in brain: pharmacogenetics, neuropharmacology, neurotoxicology, and potential therapeutic applications.
Onaivi ES
Int Rev Neurobiol; 2009; 88():335-69. PubMed ID: 19897083
[TBL] [Abstract][Full Text] [Related]
23. Endocannabinoid system in food intake and metabolic regulation.
Jesudason D; Wittert G
Curr Opin Lipidol; 2008 Aug; 19(4):344-8. PubMed ID: 18607180
[TBL] [Abstract][Full Text] [Related]
24. The role of endocannabinoids in pain modulation.
Zogopoulos P; Vasileiou I; Patsouris E; Theocharis SE
Fundam Clin Pharmacol; 2013 Feb; 27(1):64-80. PubMed ID: 23278562
[TBL] [Abstract][Full Text] [Related]
25. Endocannabinoids in the immune system and cancer.
Parolaro D; Massi P; Rubino T; Monti E
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):319-32. PubMed ID: 12052046
[TBL] [Abstract][Full Text] [Related]
26. Endocannabinoids as novel mediators of liver diseases.
Mallat A; Lotersztajn S
J Endocrinol Invest; 2006; 29(3 Suppl):58-65. PubMed ID: 16751709
[TBL] [Abstract][Full Text] [Related]
27. Endocannabinoids and basal ganglia functionality.
Fernández-Ruiz J; Lastres-Becker I; Cabranes A; González S; Ramos JA
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):257-67. PubMed ID: 12052041
[TBL] [Abstract][Full Text] [Related]
28. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors.
Castillo A; Tolón MR; Fernández-Ruiz J; Romero J; Martinez-Orgado J
Neurobiol Dis; 2010 Feb; 37(2):434-40. PubMed ID: 19900555
[TBL] [Abstract][Full Text] [Related]
29. The endocannabinoid system and psychiatric disorders.
Parolaro D; Realini N; Vigano D; Guidali C; Rubino T
Exp Neurol; 2010 Jul; 224(1):3-14. PubMed ID: 20353783
[TBL] [Abstract][Full Text] [Related]
30. Homeostatic changes of the endocannabinoid system in Parkinson's disease.
Pisani V; Madeo G; Tassone A; Sciamanna G; Maccarrone M; Stanzione P; Pisani A
Mov Disord; 2011 Feb; 26(2):216-22. PubMed ID: 21412829
[TBL] [Abstract][Full Text] [Related]
31. Effects induced by cannabinoids on monoaminergic systems in the brain and their implications for psychiatric disorders.
Esteban S; García-Sevilla JA
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jul; 38(1):78-87. PubMed ID: 22133541
[TBL] [Abstract][Full Text] [Related]
32. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
Fernández-Ruiz J; Romero J; Ramos JA
Handb Exp Pharmacol; 2015; 231():233-59. PubMed ID: 26408163
[TBL] [Abstract][Full Text] [Related]
33. The role of the endocannabinoid system in eating disorders: pharmacological implications.
Marco EM; Romero-Zerbo SY; Viveros MP; Bermudez-Silva FJ
Behav Pharmacol; 2012 Sep; 23(5-6):526-36. PubMed ID: 22785439
[TBL] [Abstract][Full Text] [Related]
34. Cannabinoid receptors and their role in neuroprotection.
van der Stelt M; Di Marzo V
Neuromolecular Med; 2005; 7(1-2):37-50. PubMed ID: 16052037
[TBL] [Abstract][Full Text] [Related]
35. The Endocannabinoid System and Anxiety.
Lisboa SF; Gomes FV; Terzian AL; Aguiar DC; Moreira FA; Resstel LB; Guimarães FS
Vitam Horm; 2017; 103():193-279. PubMed ID: 28061971
[TBL] [Abstract][Full Text] [Related]
36. The endocannabinoid system: a revolving plate in neuro-immune interaction in health and disease.
Tanasescu R; Gran B; Constantinescu CS
Amino Acids; 2013 Jul; 45(1):95-112. PubMed ID: 22367605
[TBL] [Abstract][Full Text] [Related]
37. Endocannabinoid system in neurodegenerative disorders.
Basavarajappa BS; Shivakumar M; Joshi V; Subbanna S
J Neurochem; 2017 Sep; 142(5):624-648. PubMed ID: 28608560
[TBL] [Abstract][Full Text] [Related]
38. Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies.
Fernández-Ruiz J; Gómez-Ruiz M; García C; Hernández M; Ramos JA
Methods Enzymol; 2017; 593():175-198. PubMed ID: 28750802
[TBL] [Abstract][Full Text] [Related]
39. Medicinal Chemistry approach, pharmacology and neuroprotective benefits of CB
Ferrisi R; Ceni C; Bertini S; Macchia M; Manera C; Gado F
Pharmacol Res; 2021 Aug; 170():105607. PubMed ID: 34089867
[TBL] [Abstract][Full Text] [Related]
40. Endocannabinoid signaling in neurotoxicity and neuroprotection.
Pope C; Mechoulam R; Parsons L
Neurotoxicology; 2010 Sep; 31(5):562-71. PubMed ID: 19969019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
